ASCO 2019 — Adjuvant ipilimumab yields sustained benefit in stage 3 melanoma


  • David Reilly
  • Oncology Conference reports
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Adjuvant ipilimumab maintained benefits across survival outcomes at 7 years of follow-up of the European Organisation for Research and Treatment of Cancer (EORTC) 18071 phase 3 trial in patients who underwent complete resection for high-risk, stage 3 cutaneous melanoma.

Why this matters

  • Ipilimumab received initial approval on the basis of significantly extended recurrence-free survival (RFS; P=.0013).

Study design

  • Long-term follow-up of the EORTC 18071 phase 3 trial in 951 patients who underwent complete resection for stage 3 cutaneous melanoma (excluding lymph node metastasis ≤1 mm/in-transit metastasis).
  • Randomization: 475 patients received ipilimumab, 476 patients received placebo.
  • Funding: Bristol-Myers Squibb.

Key results

  • Median follow-up, 6.9 years.
  • 7-year RFS with ipilimumab was 39.2% vs 30.9% with placebo.
    • Median RFS with ipilimumab was 2.7 years vs 1.5 with placebo (HR, 0.75; P=.0004).
  • 7-year distant metastasis-free survival (DMFS) with ipilimumab was 44.5% vs 36.9% with placebo.
    • Median DMFS with ipilimumab was 5.0 years vs 2.4 years with placebo (HR, 0.76; P=.0018).
  • 7-year OS with ipilimumab was 60.0% vs 51.3% with placebo.
    • Median OS was not reached with ipilimumab vs 7.8 years with placebo (HR, 0.73; P=.0021).

Limitations

  • No significant factors predictive of outcomes were identified.